2009 Form 990-PF - Bill & Melinda Gates Foundation

BILL & MELINDA GATES FOUNDATION 56-2618866
FORM 990PF, PART XV - GRANTS AND CONTRIBUTIONS PAID DURING THE YEAR
RELATIONSHIP TO SUBSTANTIAL CONTRIBUTOR
AND
ATTACHMENT 18 (CONT'D)
RECIPIENT NAME AND ADDRESS FOUNDATION STATUS OF RECIPIENT PURPOSE OF GRANT OR CONTRIBUTION AMOUNT
550 FIRST AVENUE 509(A)(1)
GBH-SC1-81
NEW YORK, NY 100166481
ONLY SURVIVE IN THE PRESENCE OF AN ENZYME
SUPPLIED IN SPECIAL DRINKING WATER, ALLOWING
THOSE ADMINISTERING THE VACCINE TO REGULATE
ITS COLONIZATION.
NEW YORK UNIV NONE VICTOR NUSSENZWEIG OF THE NEW YORK UNIVERSITY
100,000.
550 FIRST AVENUE 509(A)(1)
GBH-SC1-81
NEW YORK, NY 100166481
SCHOOL OF MEDICINE IN THE U.S. SEEKS TO
DEVELOP A SMALL MOLECULE DRUGS TO INHIBIT KEY
KINASE ENZYMES IN THE MALARIA PARASITE THAT
ARE THOUGHT TO CONTROL LATENCY IN PARASITE
INFECTIONS. SUCH FUNDAMENTAL KNOWLEDGE MAY
ENABLE NEW TOOLS TO CLEAR THE LATENT FORMS OF
P. VIVAX PARASITES OR BLOCK TRANSMISSION OF
THE DISEASE BY TARGETING SPOROZOITES.
NEW YORK UNIV NONE TO SUPPORT NEW YORK UNIVERSITY'S LEADERSHIP
132,000.
550 FIRST AVENUE 509(A)(1)
GBH-SC1-81
NEW YORK, NY 100166481
ROLE IN THE GLOBAL ADMINISTRATIVE LAW NETWORK
NEW YORK UNIV NONE TO PROVIDE CONTINUED SUPPORT TO DETERMINE
1,520,998.
550 FIRST AVENUE 509(A)(1)
GBH-SC1-81
NEW YORK, NY 100166481
WHETHER THE V3 LOOP OF GP120 CAN INDUCE
BROADLY REACTIVE, CROSS-NEUTRALIZING
ANTIBODIES THAT WILL PROTECT AGAINST INFECTION
WITH HIV-1
NEW YORK UNIV NONE TO PROVIDE CONCEPTUAL AND EMPIRICAL
1,305,855.
550 FIRST AVENUE 509(A)(1)
GBH-SC1-81
NEW YORK, NY 100166481
FOR PUBLIC DISCLOSURE
183 OF 519
FOUNDATIONS FOR POLICY DEVELOPMENT AIMED AT
EXPANDING ACCESS TO FINANCIAL SERVICES FOR
LOW-INCOME INDIVIDUALS IN DEVELOPING COUNTRIES
ATTACHMENT 18